

Sensitivity Range for Ototoxicity (SRO): Screening Method to Improve Access

Dawn Konrad-Martin, PhD, CCC-A
NCRAR

Jake Hulswit, BS
NCRAR

VA



**U.S. Department
of Veterans Affairs**

Veterans Health
Administration
*Office of Research &
Development*

NATIONAL CENTER FOR REHABILITATIVE AUDITORY RESEARCH

Outline

Earlier Detection

Individualized SRO

Measurement considerations

Portability

Conclusions

Citations

VA



U.S. Department
of Veterans Affairs

Veterans Health
Administration
*Office of Research &
Development*

Identifying Ototoxicity

Sensitivity (hit rate)

Percentage of times ears with hearing change identified as having hearing change by the experimental measure

Specificity (correct rejection rate)

Percentage of times ears with no hearing change are correctly labeled as no change by the experimental measure

Reliability (test-retest)

Determine size change (e.g., in pure-tone threshold or OAE amplitude) likely to be real and not random variability

Significantly different change with 0.05 level of confidence provides 95% probability that change is real

Time Efficiency & Out of the booth access (clinically practical)

Inter-professional Collaborative Practice (IPP)



U.S. Department
of Veterans Affairs

Veterans Health
Administration
*Office of Research &
Development*

Monitoring Principles

High- to low- frequency progression

High-frequency testing is reliable (Fausti et al., 1998; Frank, 1990; Frank & Driesbach, 1991; Gordon et al., 2005)

High-frequency testing is sensitive (Dreschler et al., 1989; Fausti et al. 1984; Jacobson et al., 1969; Ress et al., 1999; Tange et al., 1985; Van der Hulst et al., 1988; Fausti et al., 1993; Fausti et al., 1994)

Studies have shown testing in 1/6th – octave intervals provides earlier detection (Fausti et al., 2003; Vaughan et al., 2003)

Testing in 1/3rd – octave intervals provides similar sensitivity and false positive rates

Individualized protocols targeting the ***highest frequencies*** a person can hear



U.S. Department
of Veterans Affairs

Veterans Health
Administration
Office of Research &
Development

Exposed Ears with HFA Changes

Compared with conditional audiometry, HFA had greater sensitivity in detecting changes in patients receiving ototoxic drugs

Jacobson et al., 1969; Fausti et al., 1984, 1992;
Tange et al., 1985; Rappaport et al., 1985;
Dreschler et al., 1989; Kopelman et al., 1988

VA



U.S. Department
of Veterans Affairs

Veterans Health
Administration
*Office of Research &
Development*

Individualized Sensitive Range for Ototoxicity (SRO)

S = Sensitive, detects ototoxicity 90% of the time

R = Range, 1 octave 1/6 octave steps (7 frequencies) at the upper limits of hearing

O = Ototoxicity, early detection is key

Most initial changes seen within **one octave** below the highest audible frequency and the range for each **individual is unique** and specific to their hearing configuration

A sensitive range for ototoxicity (SRO) is the uppermost frequency with a threshold ≤ 100 dB SPL and 6 lower consecutive frequencies in 1/6th octave steps




U.S. Department
of Veterans Affairs

Veterans Health
Administration
*Office of Research &
Development*

Individualized SRO

Highest Audible Frequency



ASHA Significant Shift Criteria

Presence/absence of hearing threshold change defined as¹

≥ 20 dB change at any 1 test frequency

≥ 10 dB change at any 2 consecutive test frequencies

Loss of response at 3 consecutive test frequencies

Low false positive rates for ASHA criteria

Within the conventional audiometric frequency range

Within the sensitive range for ototoxicity (SRO)²



U.S. Department
of Veterans Affairs

Veterans Health
Administration

Office of Research &
Development

Non-exposed adults: Ears with ASHA Shifts in HFA (Booth vs. Ward)

Earphone Type	Booth		Ward		Frequency Range
	≥ 20 dB at 1 Frequency	≥ 10 dB at 2 Consecutive Frequencies	≥ 20 dB at 1 Frequency	≥ 10 dB at 2 Consecutive Frequencies	
Koss Pro/4X*	0%	0%	0%	7%	2, 5-16
ER-4B*	0%	0%	0%	0%	2, 5-16
Sennheiser HDA 200**	0%	2%	n/a	n/a	8-16



U.S. Department of Veterans Affairs

Veterans Health Administration
Office of Research & Development

HFA has good specificity in booth and ward

Most Exposed Ears Have Hearing Shifts within SRO


	Total (Ears)	Hit	Miss	Initial Change on SRO
AMG	54	46	8	85%
Cisplatin	226	207	19	92%
Carboplatin	59	50	9	85%
Total	339	303	36	89%



U.S. Department
of Veterans Affairs

Veterans Health
Administration
*Office of Research &
Development*

Individualized SRO Initial Ototoxicity Detection



Frequency Reference to 100 dB SPL Threshold



U.S. Department
of Veterans Affairs

Veterans Health
Administration
Office of Research &
Development

Portability

For greater accessibility, portable audiometers and diagnostic tools are available for monitoring

Ototoxicity Identification Device

Portable handheld device

Time-efficient, reliable and sensitive
early detection

Noise monitoring

500 – 20,000 Hz

1/6 octave capability



This Photo by Unknown Author is licensed under [CC BY-SA](#)

High Frequency Audiometry

A portable, handheld audiometer-like device that will enable ward testing of ototoxicity



Measurement Considerations

Audiometer

- Calibration, portability, octave capability

Listening check

- High frequencies, High Output

Earphone placement

Stimulus Tone

- Pulsed
- Increased duration of tone

Ambient Noise

- Single-walled vs. Double-walled
- Hospital ward testing



Earphone Selection

Reliable high frequency capability

ER-4B (Gordon et al., 2005)

Senheiser HAD 200 (Frank et al., 2001)

KOSS (Gordon et al., 2005) all reliable for high frequency OM monitoring in ward

Conclusions

Evidence-based
protocol



High frequencies are
reliable

Time-efficient
protocol



Sensitive Range for
Ototoxicity (SRO) exists
~90% initial detection
rate using SRO

Portability



Only 7 frequencies in
SRO

Oto Identification Device
Earphones can be used
on ward

Citation

Reuse/Redistribution of this powerpoint is permitted with proper recognition of VA RR&D NCRAR. Cite the powerpoint as:

- Konrad-Martin, D; Hulswit, J. (2020). “Sensitivity Range for Ototoxicity (SRO): Screening Method to Improve Access”. VA RR&D National Center for Rehabilitative Auditory Research (NCRAR), September 2020



U.S. Department
of Veterans Affairs

Veterans Health
Administration
*Office of Research &
Development*

References

- Dreschler, W. V., vd Hulst, R. J. A. M., Tange, R. A., & Urbanus, N. A. M. (1989). Role of high-frequency audiometry in the early detection of ototoxicity: II. Clinical aspects. *Audiology*, 28(4), 211-220.
- D Ress, Bradford., Sridhar, K. S., Balkany, T. J., Waxman, G. M., Stagner, B. B., & Lonsbury-Martin, B. L. (1999). Effects of cis-platinum chemotherapy on otoacoustic emissions: The development of an objective screening protocol. *Otolaryngology-Head and Neck Surgery*, 121(6), 693-701.
- Fausti, S. A., Frey, R. H., Henry, J. A., Olson, D. J., & Schaffer, H. I. (1993). High-frequency testing techniques and instrumentation for early detection of ototoxicity. *Journal of rehabilitation research and development*, 30, 333-333.
- Fausti, S.A., Frey, R.H., Henry, J.A., Olson, D.J., & Schaffer, H.I. (1992). Early detection of ototoxicity using high-frequency, tone-burst-evoked auditory brainstem responses. *J Am Acad Audiol*, 3(6), 397-404.
- Fausti, S. A., Henry, J. A., Hayden, D., Phillips, D. S., & Frey, R. H. (1998). Intrasubject reliability of high-frequency (9-14 kHz) thresholds: Tested separately vs. following conventional-frequency testing. *JOURNAL-AMERICAN ACADEMY OF AUDIOLOGY*, 9, 147-152.
- Fausti, S. A., Larson, V. D., Noffsinger, D., Wilson, R. H., Phillips, D. S., & Fowler, C. G. (1994). High-frequency audiometric monitoring strategies for early detection of ototoxicity. *Ear and hearing*, 15(3), 232-239.
- Fausti, S. A., Rappaport, B. Z., Schechter, M. A., Frey, R. H., Ward, T. T., & Brummett, R. E. (1984). Detection of aminoglycoside ototoxicity by high-frequency auditory evaluation: selected case studies. *American journal of otolaryngology*, 5(3), 177-182.
- Frank, T., 1990, "High Frequency Hearing Threshold Levels Using a Beltone 2000 Audiometer and Sennheiser HD 250 Earphones," *Ear and Hearing*, 11, 450-454.
- Frank, T. and Dreisbach, L., 1991, "Repeatability of High Frequency Thresholds," *Ear and Hearing*, 12, 294-295.
- Frank, T. (2001). High-frequency (8 to 16 kHz) reference thresholds and intrasubject threshold variability relative to ototoxicity criteria using a Sennheiser HDA 200 earphone. *Ear and hearing*, 22(2), 161-168.
- Gordon, J. S., Phillips, D. S., Helt, W. J., Konrad-Martin, D., & Fausti, S. A. (2005). Evaluation of insert earphones for high-frequency bedside ototoxicity monitoring. *Journal of Rehabilitation Research & Development*, 42(3).
- Henry, J. A., Jastreboff, M. M., Jastreboff, P. J., Schechter, M. A., & Fausti, S. A. (2003). Guide to conducting tinnitus retraining therapy initial and follow-up interviews. *Journal of rehabilitation research and development*, 40(2), 157-178.
- Jacobson E. J., Downs M. P., Fletcher J. L. Clinical findings in high frequency thresholds during known ototoxic drug usage. *J Audit Res* 1969; 9: 379
- Kopelman, J., Budnick, A. S., Sessions, R. B., Kramer, M. B., & Wong, G. Y. (1988). Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing. *The Laryngoscope*, 98(8), 858-864.
- Tange, R. A., Dreschler, W. A., & Van der Hulst, R. J. A. M. (1985). The importance of high-tone audiometry in monitoring for ototoxicity. *Archives of oto-rhino-laryngology*, 242(1), 77-81.
- Van Der Hulst, R. J. A. M., Dreschler, W. A., & Urbanus, N. A. M. (1988). High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. *Annals of Otolaryngology, Rhinology & Laryngology*, 97(2), 133-137.



U.S. Department
of Veterans Affairs

Veterans Health
Administration
Office of Research &
Development